Trace an author's published raw data, reproducibility notes, and citation‑backed summaries.
Press Enter ↵ to solve
Fuel Your Discoveries
"Imagination is more important than knowledge. Knowledge is limited. Imagination encircles the world."
- Albert Einstein
Quick Explanation
Copied
Qing Dai — scientific strength check (evidence-based, skeptical)
Based on the specific works you provided, Qing Dai shows cross-domain experimental skills (e.g., molecular redox/epigenetics, renal fibrosis signaling, transcriptomics/genomics, sequencing-method development). However, author disambiguation is a major risk because “Qing Dai” matches multiple distinct authors in OpenAlex, so scientific credit may be mis-assigned.
Key strengths: mechanistic multi-assay designs (ChIP/Co-IP/MS/functional assays), inclusion of appropriate controls, and—in at least one case—quantitative performance metrics for a sequencing chemistry problem. Key weaknesses: some studies appear underpowered, rely on cell lines/single-species models, and sometimes lack open data deposition or external validation.
Long Explanation
Author Review: Qing Dai (critique of scientific strength)
Epistemic status: I can only analyze what you provided. Importantly, the name “Qing Dai” is ambiguous in scholarly databases; your supplied dataset does not fully prove these papers all belong to the same person. Where attribution is uncertain, I flag it.
1) Evidence set & attribution risk (critical)
Your input contains multiple paper records with different topics (ONT multiplexing chemistry, myocardial redox/epigenetic control, renal fibrosis palmitoylation, AML biomarker panels, virology host response, etc.). All paper identities are anchored by DOIs you provided, but your input does not provide enough author-page metadata to guarantee all are authored by the same “Qing Dai” rather than different researchers sharing the same name.
Consequence: scientific scoring below measures the quality of the provided works, not a proven life-track record of one individual across the literature.
From the ONT multiplexed sequencing paper you provided, the PLP-based workflows show large reductions in barcode misassignment and strong precision/recall.
Evidence notes (skeptical)
What’s strong: The provided metrics quantify misassignment reductions by orders of magnitude and report precision/recall at the workflow level (Standard vs SFB vs PLP vs SFB+PLP) in multiple sequencing conditions.
Primary limitation: Your excerpt flags that broader generalizability across ONT kits/flows and additional real-community ground truth are not fully established.
Reproducibility risk: you note pending/limited detail on data deposition (BioProject accession pending; GitLab repository pending). That can slow independent verification even if methods are plausible.
The myocardial injury paper you supplied proposes a mechanistic cascade linking CME-triggered iNOS-driven S-nitrosylation of USP16 to regulation of KDM1A ubiquitination/degradation, ultimately disturbing glutathione homeostasis by repressing GCLM/GLS transcription.
Rigor & blind spots
Rigor signals: The excerpt you provided includes orthogonal evidence types (biochemistry for S-nitrosylation; promoter binding/activity via ChIP/re-ChIP; proteomics deposition; in vivo and in vitro models; genetic perturbations including point mutations).
Major uncertainty: No gene-knockout animals or human clinical validation are reported in your provided limitation notes. That reduces confidence that the mechanism generalizes beyond the modeled pathways and species.
4) Protein lipidation & fibrosis: strong translational wiring, but still model-bound
In the renal fibrosis palmitoylation axis study you supplied, the central claim is that DHHC9-mediated palmitoylation of β-catenin promotes β-catenin degradation (anti-fibrotic), whereas APT1-mediated depalmitoylation stabilizes β-catenin (pro-fibrotic), with tubular cell-specific genetics used in UUO and IRI models.
Counterpoints / missing validation
Model limitations: The excerpt you provided flags distal-tubule–dominant Cre efficiency concerns and possible off-target effects from broad inhibitors (e.g., 2-BP).
Sex and compensatory biology: Male-only mouse usage and potential compensation by other PATs (beyond DHHC9) are noted as blind spots in your provided limitations.
5) Mixed evidence quality across domains (biomarkers/reviews vs mechanistic wet-lab)
Your dataset also includes: (i) a narrative/clinical review on complementary therapies for IBD (), and (ii) an AML microRNA biomarker paper with observational cohort + TCGA corroboration (). These types of work typically warrant lower mechanistic confidence than multi-perturbation functional experiments.
A balanced reading: cross-domain output can be a strength (method development + mechanistic biology), but it can also dilute depth if experimental designs are not consistently causal.
6) Quantitative visualization: AML biomarker discrimination (single metric)
From the provided AML biomarker excerpt, AUC for AML vs controls is reported as 0.654.
Skeptical interpretation
What AUC implies: An AUC around 0.65 indicates modest discrimination, not a near-diagnostic biomarker. In biomarker papers, causal interpretation is limited because associations can reflect confounding or treatment status.
Specific blind spots mentioned in your excerpt: single-center design and lack of independent external validation cohort.
7) Overall scientific strength score (based on provided works only)
Scientific quality (causal/mechanistic strength): moderate-to-high when the work includes multi-assay mechanistic chains (e.g., redox/epigenetic axes, lipidation/degradation logic) and quantitative readouts. Reproducibility and generalization confidence: mixed; some items mention pending data deposits or model-bound limitations.
Top red flag (for “author strength”): ambiguous author identity (“Qing Dai” collisions). Without a verified ORCID or disambiguated author page, a strong score could be mis-assigning credit.
8) How to improve the evidence for a higher-confidence author review
Provide a single verified author identifier (ORCID or one specific institutional profile) for “Qing Dai,” so each DOI can be correctly attributed.
For each DOI, share whether raw data are deposited (e.g., SRA/GEO/PRIDE) and whether accession IDs are explicit—this drives reproducibility strength.
Include at least one external validation study (biomarkers, generalization across ONT kits, independent cohorts/patient subsets).
Useful next steps inside BGPT
Feedback:
Updated: May 01, 2026
BGPT Author Review
Scientific Quality
60%
Moderately strong scientific output in the provided set: multiple studies describe multi-constraint mechanistic chains with orthogonal assays (e.g., redox/epigenetic regulation; lipidation/degradation logic; quantitative sequencing performance metrics). However, scientific credit is at risk because “Qing Dai” is name-ambiguous in bibliographic indices, and the provided dataset does not fully prove all DOIs map to the same individual. Reproducibility/generalization confidence is also mixed (some studies flag limited external validation, pending data deposition, and strong dependence on specific model systems).
Communication Quality
70%
The supplied paper summaries are structured and mechanistically oriented with explicit methods/endpoints and stated limitations. However, some items omit key numeric details (e.g., consistent group sizes) and data-deposition specifics, which weakens transparency. Overall, communication appears adequate-to-strong but not consistently publication-grade in the excerpts you provided.
Author Novelty
60%
Several works appear incremental-mechanistic but not paradigm-shifting (epigenetic/redox cascades; palmitoylation control of fibrosis). The ONT barcoding chemistry work seems practically novel (workflow-level crosstalk reduction with quantitative metrics). Novelty can’t be reliably judged across the full career because the author set may be mixed by name ambiguity.
Scientific Rigor
60%
Rigor is mixed: mechanistic studies include multiple perturbation types and orthogonal evidence, which boosts causal plausibility. But multiple blind spots recur in the excerpted limitations: model-bound generalization (single species, cell lines, single disease model), incomplete clinical validation, potential inhibitor off-targets, small/limited cohorts, and sometimes unclear or pending raw-data access. These factors reduce overall rigor confidence.
None (not enough quantitative per-paper raw tables were provided to run a rigorous cross-study computation).
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The observed improvements in sequencing fidelity are primarily due to demultiplexing parameter tuning rather than biochemical library changes; the workflow-level precision/recall and blank leakage reductions argue upstream causality in the provided ONT study.
Renal fibrosis protection in the DHHC9 axis is mainly a downstream effect of generic palmitoylation changes rather than specific β-catenin Cys300 palmitoylation; the mechanistic emphasis on Cys300 plus genetic models makes the generic-effect explanation less parsimonious.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight